Project description
A skin probiotic against acne
Acne constitutes one of the most prevalent skin conditions, affecting the quality of life of millions of people worldwide. Most topical solutions in the market today are either ineffective or cause severe side effects. The EU-funded SkinMicrobiome project is working on a cosmetic product for acne-prone skin that is based on disruptive technology developed by S-Biomedic, a leader in the field of skin microbiome. The SkinMicrobiome acne product has the capacity to directly modulate the skin microbiome, responsible for the development of acne, while additional applications in dermatology are also possible. The proprietary technology is expected to reduce current treatments from years to weeks and prevent relapse episodes of acne.
Objective
S-Biomedic has developed a disruptive technology to directly modulate the skin microbiome, enabling a wide range of applications in dermatology. The first product is a cosmetic for acne prone skin (TRL6) with proven efficacy and safety in an area where competing products are either ineffective or cause severe side-effects.
Acne is amongst the 10 most prevalent diseases globally and the main reason for people to consult a dermatologist. It affects the life quality of millions of Europeans and represents a market of €4.4 billion. S-Biomedic’s novel skin probiotic product will be launched in 2021 in selected European countries, and will allow reducing current treatments from years to weeks and preventing the actual relapse episodes of acne.
S-Biomedic is leading the skin microbiome field based on a unique combination of approach, technology and careful IPR protection. Backed by global industrial partners with an unparalleled reputation in the personal care industries, such as Johnson & Johnson, DSM and Beiersdorf, S-Biomedic has successfully accelerated its R&D and turned its platform technology into a high-potential product pipeline. However, the ambitious challenge posed by the launch of a new cosmetic product in the market can only be met to its full potential with the support of the EIC pilot.
The SkinMicrobiome project will support S-Biomedic in the route to market and accelerate its growth, enabling sales >€55M by 2028, positioning it among the Top 10 acne brands globally, with a projected market share of 2,58%. SkinMicrobiome will allow to hire employees with commercial and marketing background, who will complement a multidisciplinary team led by excellent business and scientific professionals. SkinMicrobiome will become a key cornerstone for the successful launch of the first highly innovative cosmetic and will enable S-Biomedic to lead at the forefront of microbiome-based solutions not only in Europe but also on a global level.
Fields of science
Programme(s)
Funding Scheme
SME-2b - SME Instrument (grant only and blended finance)Coordinator
2340 BEERSE
Belgium
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.